---
title: "ATEC: Procedure adoption surged, but biologics leakage and market softness cut FY2026 guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303643473.md"
description: "Q3 revenue rose 13% and procedure volumes grew 20%, while biologics leakage and softer thoracolumbar demand constrained growth. FY2026 revenue guidance was lowered to $862 million; Adjusted EBITDA guidance is $137 million.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-10-29T23:19:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303643473.md)
  - [en](https://longbridge.com/en/news/303643473.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303643473.md)
generator: "portal-rs"
---

# ATEC: Procedure adoption surged, but biologics leakage and market softness cut FY2026 guidance

Q3 revenue rose 13% and procedure volumes grew 20%, while biologics leakage and softer thoracolumbar demand constrained growth. FY2026 revenue guidance was lowered to $862 million; Adjusted EBITDA guidance is $137 million.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ATEC.US](https://longbridge.com/en/quote/ATEC.US.md)

## Related News & Research

- [ATEC: Surgical demand strengthened, but biologics attachment constrained Q3 revenue](https://longbridge.com/en/news/303621217.md)
- [ATEC Q3 2026 Earnings: Biologics Weakness Limits Revenue Growth](https://longbridge.com/en/news/303624186.md)
- [Did Alphatec's Fall Catch You Out? What Investors Missed](https://longbridge.com/en/news/303089224.md)
- [JP Morgan maintains Alphatec Holdings at Overweight, lowers price target to $15 from $16](https://longbridge.com/en/news/303811177.md)
- [Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop?](https://longbridge.com/en/news/303867113.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**